510(k) Report

510(k) · Cleared

Cleared

Quanta Lite Lyme Igg Elisa

K984222510(k) TraditionalCleared Apr 15, 1999141-day reviewClass II21 CFR 866.3830

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Inova Diagnostics, Inc. · LSR Reagent, Borrelia Serological Reagent

Cleared on Apr 15, 1999 after a 141-day review. FDA’s file for it is a 510(k) statement, which names no predicate.

Decided
Apr 15, 1999
Review
141 days
Class
Class II
Product code
LSR
Recalls
None
Predicates
0

FDA’s file for it is a 510(k) statement, which names no predicate.

FIG. 1 — Lineage of K984222Source: FDA 510(k) database · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA 510(k) statement (indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in LSR? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new LSR device

  1. #1 K254295 Sofia Lyme FIA; Sofia 2 Campylobacter FIAscore 12.5 · 4 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against?

FDA’s file for it is a 510(k) statement, which names no predicate.

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

How does its category compare?

All LSR devices

LSR Reagent, Borrelia Serological Reagent: FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · LSR

2in 2025

2007: 12008: 22009: 22010: 12012: 32013: 22015: 12016: 12017: 62018: 32019: 42020: 32021: 62022: 12023: 12024: 12025: 22026 (partial year): 1
2007high 6 (2017) · low 0 (2011)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · LSR

133in 2021

2012: 155 days median2017: 150 days median2018: 92 days median2019: 86 days median2020: 91 days median2021: 133 days median
2007high 155 (2012) · low 86 (2019)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · LSR

1in 2025

2013: 12021: 22025: 1
2007high 2 (2021) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · LSR

1in 2025

2008: 22011: 12014: 532015: 252016: 102017: 92018: 42019: 152020: 72021: 42022: 12023: 22025: 1
2007high 53 (2014) · low 0 (2007)2025

MAUDE reports naming product code LSR, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20071—00
20082—02
20092—00
20101—00
20110—01
2012315500
20132—10
20140—053
20151—025
20161—010
2017615009
201839204
2019486015
202039107
2021613324
20221—01
20231—02
20241—00
20252—11
20261—0—

What is it indicated for?

The QUANTA Lite™ Lyme B. burgdorferi igG ELISA kit is an enzyme-linked immunosorbent assay (ELISA) for the initial (first-step) qualitative detection of IgG antibodies to B. burgdorferi, the agent of Lyme disease (Lyme borreliosis), in human serum. This ELISA is intended to provide presumptive evidence of the presence of antibodies to B. burgdorferi. Equivocal or positive results should be followed by a standardized second-step supplemental procedure…

Read the full statement (120 words)

The QUANTA Lite™ Lyme B. burgdorferi igG ELISA kit is an enzyme-linked immunosorbent assay (ELISA) for the initial (first-step) qualitative detection of IgG antibodies to B. burgdorferi, the agent of Lyme disease (Lyme borreliosis), in human serum. This ELISA is intended to provide presumptive evidence of the presence of antibodies to B. burgdorferi. Equivocal or positive results should be followed by a standardized second-step supplemental procedure such as Western blot assays. Positive results on a second-step assay can support a clinical diagnosis of Lyme disease. Diagnosis of Lyme disease should be based on history, physical findings, and other laboratory data in addition to anti-B. burgdorferi results. Negative resuits should not be the sole basis for exclusion of B. burgdorferi infection.

Indications for use read by OCR from a scanned FDA 510(k) statement, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K984222: Quanta Lite Lyme Igg Elisa.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K984222

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Page last updated Nov 3, 2026